Pitfalls in integrated CT-PET of the thorax: Implications in oncologic imaging

Journal of Thoracic Imaging

Volumn 21, Issue 2, 2006, Pages 111-122

  Truong, Mylene T ^a   Pan, Tinsu ^a   Erasmus, Jeremy J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Computed tomography; Malignancy; Positron emission tomography; Thorax

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GERMANIUM;

ARTIFACT; BREATHING MECHANICS; BREATHING PATTERN; BROWN ADIPOSE TISSUE; CANCER CYTODIAGNOSIS; CANCER RECURRENCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; EXPIRATORY FLOW RATE; FALSE POSITIVE RESULT; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; IMAGE RECONSTRUCTION; INFLAMMATORY INFILTRATE; LARYNX CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOMA; PLEURODESIS; POSITRON EMISSION TOMOGRAPHY; THERMOGENESIS;

EID: 33745225440     PISSN: 08835993     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005382-200605000-00003     Document Type: Conference Paper

References (61)

1. Vansteenkiste J, Fischer BM, Dooms C, et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol. 2004;9:531-540.
2. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;9315:1388-1393.
3. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer. 2004-2:175-181.
4. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable nonsmall cell lung cancer. J Thorac Cardiovasc Surg. 2003;6:1943-1951.
5. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol. 2004;12:2357-2362.
6. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;14:2651-2657.
7. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology. 2003;2:526-533.
8. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;25:2500-2507.
9. Kinahan PE, Townsend DW, Beyer T, et al. Attenuation correction for a combined 3D PET/CT scanner. Med Phys. 1998;10:2046-2053.
10. Cook GJ, WegnerEA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med. 2004;2:122-133.
11. Goerres GW, Burger C, Kamel E, et al. Respiration-induced attenuation artifact at PET/CT: technical considerations. Radiology. 2003;3:906-910.
12. Beyer T, Antoch G, Blodgett T, et al. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging. 2003;4:588-596.
13. Osman MM, Cohade C, Nakamoto Y, et al. Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. Eur J Nucl Med Mol Imaging. 2003;4:603-606.
14. Kinahan PE, Hasegawa BH, Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med. 2003;3:166-179.
15. Bai C, Kinahan PE, Brasse D, et al. An analytic study of the effects of attenuation on tumor detection in whole-body PET oncology imaging. J Nucl Med. 2003;11:1855-1861.
16. Nakamoto Y, Osman M, Cohade C, et al. PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. J Nucl Med. 2002;9:1137-1143.
17. Sarikaya I, Yeung HW, Erdi Y, et al. Respiratory artefact causing malpositioning of liver dome lesion in right lower lung. Clin Nucl Med. 2003;11:943-944.
18. Osman MM, Cohade C, Nakamoto Y, et al. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med. 2003;2:240-243.
19. Pan T, Mawlawi O, Nehmeh SA, et al. Attenuation correction of PET images with respiration-averaged CT images in PET/CT. J Nucl Med. 2005;9:1481-1487.
20. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;4:254-261.
21. Goerres GW, Kamel E, Heidelberg TN, et al. PET-CT image coregistration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging. 2002;3:351-360.
22. Goerres GW, Kamel E, Seifert B, et al. Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system. J Nucl Med. 2002;11:1469-1475.
23. de Juan R, Seifert B, Berthold T, et al. Clinical evaluation of a breathing protocol for PET/CT. Eur Radiol. 2004;6:1118-1123.
24. Kayano T, Burant CF, Fukumoto H, et al. Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small intestine, kidney, muscle, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6). J Biol Chem. 1990;22:13276-13282.
25. Pappas GP, Olcott EW, Drace JE. Imaging of skeletal muscle function using (18)FDG PET: force production, activation, and metabolism. J Appl Physiol. 2001;1:329-337.
26. Goerres GW, Von SchulthessGK, Hany TF. Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. AJR Am J Roentgenol. 2002;5:1337-1343.
27. Yeung HW, Grewal RK, Gonen M, et al. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med. 2003;11:1789-1796.
28. Kostakoglu L, Wong JC, Barrington SF, et al. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med. 1996;11:1771-1773.
29. Kamel EM, Goerres GW, Burger C, et al. Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion - report of six cases. Radiology. 2002;1:153-156.
30. Hany TF, Gharehpapagh E, Kamel EM, et al. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging. 2002;10:1393-1398.
31. Truong MT, Erasmus JJ, Munden RF, et al. Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol. 2004;4:1127-1132.
32. Cohade C, Osman M, Pannu HK, et al. Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. J Nucl Med. 2003;2:170-176.
33. Cohade C, MourtzikosKA, Wahl RL. "USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT. J Nucl Med. 2003;8:1267-1270.
34. Erasmus JJ, McAdams HP, Patz JEF, et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. Am J Roentgenol. 1998;170:1369-1373.
35. Kim BT, Kim Y, Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol. 1998;4:935-939.
36. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med. 2000;41:85-92.
37. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun. 2002;9:865-870.
38. Yap CS, Schiepers C, Fishbein MC, et al. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging. 2002;9:1166-1173.
39. Lee KS, Kim Y, Han J, et al. Bronchioloalveolar carcinoma: clinical, histopathologic, and radiologic findings. Radiographies. 1997;17:1345-1357.
40. Verboom P, Van Tinteren H, Hoekstra OS, et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging. 2003;30:1444-1449.
41. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16:2142-2149.
42. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000;11:1598-1609.
43. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg. 1998;66:1876-1885.
44. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
45. Chung JH, Cho KJ, Lee SS, et al. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging. J Nucl Med. 2004;6:999-1003.
46. Ahmed Z, Shrager JB. Mediastinal talcoma masquerading as thymoma. Ann Thorac Surg. 2003;2:568-569.
47. Williams T, Gostelow B, Woods D, et al. Apical pleural mass developing following talc pleurodesis. Respir Med. 1998;2:358-359.
48. Kwek BH, AquinoSL, Fischman AJ. Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis. Chest. 2004;6:2356-2360.
49. Stein J, Eliachar I, Myles J, et al. Histopathologic study of alternative substances for vocal fold medialization. Ann Otol Rhinol Laryngol. 2000;2:221-226.
50. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;23:2708-2711.
51. Halpern BS, Dahlbom M, Waldherr C, et al. Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images. J Nucl Med. 2004;2:290-293.
52. Swisher SG, Erasmus J, Maish M, et al. 2-fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;8:1776-1785.
53. Erdi YE, Macapinlac H, Rosenzweig KE, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med. 2000;7:861-866.
54. Truong MT, Erasmus JJ, Macapinlac HA, et al. Teflon injection for vocal cord paralysis: false-positive finding on FDG PET-CT in a patient with non-small cell lung cancer. AJR Am J Roentgenol. 2004;6:1587-1589.
55. Hollinger EF, Alibazoglu H, Ali A, et al. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;2:93-98.
56. Schneider B, Bigenzahn W, End A, et al. External vocal fold medialization in patients with recurrent nerve paralysis following cardiothoracic surgery. Eur J Cardiothorac Surg. 2003;4:477-483.
57. Haddad FJ, Younes RN, Gross JL, et al. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial. World J Surg. 2004;8:749-753; discussion 53-4.
58. Marom EM, Erasmus JJ, Herndon JE II, et al. Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions. AJR Am J Roentgenol. 2002;1:105-108.
59. WeissN, Solomon SB. Talc pleurodesis mimics pleural metastases: differentiation with positron emission tomography/computed tomography. Clin Nucl Med. 2003;10:811-814.
60. Frank A, Lefkowitz D, Jaeger S, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys. 1995; 32:1495-1512.
61. Inoue T, Kim E, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med. 1995;36:788-793.